The study evaluate the effect of a membrane in polysulfone covered with vitamin E (ViE15-A, ASAHI Kasey, Tokyo, Japan) versus non-vitamin E polysulfone membrane (REXEED-15A, ASAHI Kasey, Tokyo, Japan) in critically ill patients admitted to intensive care undergoing continuous extracorporeal dialysis (CRRT). The current randomized study is designed to assess the effect on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines using ViE 15-A in comparison withe REXEED-15A. The investigators hypothezise that the ViE15-A versus REXEED-15A will have different effect on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines.
The study evaluate the effect of a membrane in polysulfone covered with vitamin E (ViE15-A, ASAHI Kasey, Tokyo, Japan) on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines in critically ill patients admitted to intensive care undergoing continuous extracorporeal dialysis (CRRT). This membrane will be compared with a non-vitamin E polysulfone membrane (REXEED-15A, ASAHI Kasey, Tokyo, Japan) and already intended for use in continuous renal support therapy. The current randomized study is designed to assess the effect on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines using ViE 15-A in comparison withe REXEED-15A. Precisely, will be evaluated 1. the effect of the filter on the reduction of the plasma levels of two pro-inflammatory cytokines (IL-1β and IL-6) and of two anti-inflammatory cytokines (IL-10, IL-8); 2. the analysis of the life modality of the monocytic cells: the patient's plasma will be used, incubated for 24 hours with U937 cells (monocyte precursor cells), necrosis cells and the percentage of apoptotic cells. The apoptotic cells will also evaluate the apoptotic pathway (evaluation of activated caspases) that led to cell death. The differences that are highlighted in the two different sampling moments become expressed Δ% with respect to the initial value Secondary outcomes will be to evaluate the clinical outcomes (haemodynamic and hematochemical parameters) in the short and long term deriving from the application of a membrane with vitamin E; for this reason, for the whole duration of the extracorporeal dialysis therapy, the same filter assigned to the patient at the time of enrollment will be used. All the other parameters of the extracorporeal treatment that can influence the results will be standardized; in particular, the flows will be fixed according to the dialysis dose criteria and re-infusion methods according to the table in the paragraph "treatment characteristics".
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Enrollment
60
The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
San Bortolo Hospital
Vicenza, Italy
RECRUITINGCopper/Zinc
In vivo comparison of ROS concentrations in two groups
Time frame: change from 24 to 72 hours
Superoxide Dismutas
In vivo comparison of ROS concentrations in two groups
Time frame: change from 24 to 72 hours
Endogenous peroxidase activity
In vivo comparison of ROS concentrations in two groups
Time frame: change from 24 to 72 hours
Nitric Oxide
In vivo comparison of ROS concentrations in two groups
Time frame: change from 24 to 72 hours
Viability
Ex vivo comparison of relative decrease of monocytes cell line incubated in plasma
Time frame: change from 24 to 72 hours
Apoptosis
Ex vivo comparison of relative decrease of monocytes cell line incubated in plasma
Time frame: change from 24 to 72 hours
Necrosis
Ex vivo comparison of relative decrease of monocytes cell line incubated in plasma
Time frame: change from 24 to 72 hours
Interleukine-6
In vivo comparison of relative reductions of inflammatory cytokines concentrations in two groups
Time frame: change from 24 to 72 hours
Interleukine -10
In vivo comparison of relative reductions of inflammatory cytokines concentrations in two groups
Time frame: change from 24 to 72 hours
Interleukine-18
In vivo comparison of relative reductions of inflammatory cytokines concentrations in two groups
Time frame: change from 24 to 72 hours
Comparison of CRRT-free days from enrollment to ICU discharge in two groups
The assessment of the effect of both hemofilters on short term clinical renal outcomes
Time frame: 7 days
Comparison of mechanical Ventilation-free days from enrollment to ICU discharge in two groups
The assessment of the effect of both hemofilters on short term clinical renal outcomes
Time frame: 7 days
Comparison of vasopressor drugs-free days in two groups
The assessment of the effect of both hemofilters on short term clinical renal outcomes
Time frame: 7 days
Comparison of ICU length of stay in two groups
The assessment of the effect of both hemofilters on short term clinical renal outcomes
Time frame: 7 days
Comparison of renal recovery in two groups
The assessment of the effect of both hemofilters on short term clinical renal outcomes
Time frame: 7 days
Comparison of CRRT-free days from enrollment to hospital discharge in two groups
The assessment of the effect of both hemofiltes on long term clinical renal outcomes
Time frame: 90 days
Comparison of need of (Intermittent Hemodialysis) IHD at hospital discarge in patients treated with vitamine E-coated membrane and non-vitamin E-coated membrane
The assessment of the effect of both hemofiltes on long term clinical renal outcomes
Time frame: 90 days
Comparison of renal recovery at hospital discharge in two groups
The assessment of the effect of both hemofiltes on long term clinical renal outcomes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 90 days